Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
"I think AZ is b being sued for over a claim for royalties."
https://www.reuters.com/article/us-astrazeneca-array-biopharma-idUSKBN1FL6O6
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/8e14257f-8bf8-4dc7-9680-9d489654d2b6
AstraZeneca revealed strong Covid-19 vaccine sales but warned it would take even longer to secure approval in the US, the world’s largest pharmaceutical market.
The UK-Swedish group said it might take until the end of the year to submit its Covid vaccine to the US regulator, after deciding to apply for full regulatory approval rather than an emergency use authorisation.
Smithy, how do you propose we humanely arrive at a world with less people?
The four horses of the Apocalypse.
In a logical market (Ha!) it should have no effect. GSK was not involved with the failed vaccine, that was being developed in partnership with Bayer. GSK are in collaboration in developing the second generation vaccine.
On the second vaccine Curevac says:
Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK
CV2CoV mRNA shows high levels of antigen production in rat model
Fast onset of strong neutralizing antibody titers after first vaccination
High cross-neutralizing capacity of induced antibodies against selected Variants of Concern
GlaxoSmithKline PLC on Friday noted a "mini-tender" offer by TRC Capital Investment Corp and recommended its shareholders reject it.
Investment firm TRC Capital intends to purchase up to 3.0 million American depositary shares at a price of USD37.10 each in cash. As described by TRC Capital, its offer is being made at a 4.5% discount to the closing price of USD38.85 per share on May 21, the last trading day before the offer commenced.
The pharmaceutical company said it "does not endorse" TRC Capital's offer and recommends that ADS holders reject the offer.
GlaxoSmithKline shares were trading 0.7% higher in London on Friday at 1,353.20 pence each. Its ADS were up 0.5% in New York at USD38.91 each.
AstraZeneca today announced that Marc Dunoyer will step down as CFO and retire from the Board, after serving in the role for seven years
Mr Dunoyer will be replaced by Aradhana Sarin, who currently serves as CFO of Alexion. AstraZeneca is in the process of acquiring Alexion and expects to complete this transaction in the third quarter of 2021
After stepping down as AstraZeneca’s CFO, Mr Dunoyer will become CEO of Alexion (which will become the Rare Disease Unit of AstraZeneca), as well as Chief Strategy Officer for AstraZeneca.
Paper preprint here:
https://www.researchsquare.com/article/rs-558954/v1
https://www.ibtimes.co.in/covid-vaccine-blood-clot-mystery-solved-scientists-claim-rare-condition-can-now-be-fixed-836785
https://www.ft.com/content/f76eb802-ec05-4461-9956-b250115d0577
Secret record of EU legal strategy meeting to determine damages:
https://www.youtube.com/watch?v=Z0tilMgntvQ